Iododoxorubicin

N/A

Report date: 2022/08/29 20:00:24
NME

Base Information

Drug NameIododoxorubicin
Drug Alias Name4-Iodo-4-deoxydoxorubicin碘多柔比星Iodo-Dox碘阿霉素4-IDX +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsAmyloidosisPlasmacytomaMultiple Myeloma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItaly
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsAmyloidosisPlasmacytomaMultiple Myeloma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A